Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
GPD2 Double Nickase Plasmid (h): sc-402698-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GPD2 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- GPD2 Double Nickase Plasmid (h) and GPD2 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting GPD2. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: GPD2 Antibody (D-12): sc-390830
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GPD2 Double Nickase Plasmid (h) | sc-402698-NIC | 20 µg | $410.00 | |||
GPD2 Double Nickase Plasmid (h2) | sc-402698-NIC-2 | 20 µg | $410.00 |
GPD2 encodes mitochondrial glycerol-3-phosphate dehydrogenase, a key flavoprotein component of the glycerophosphate shuttle that transfers cytosolic reducing equivalents into mitochondria by coupling glycerol-3-phosphate oxidation to ubiquinone reduction. This activity links glycolysis to oxidative phosphorylation, influences cellular redox balance, and supports lipid and glycerolipid metabolism through control of glycerol-3-phosphate pools. By shaping mitochondrial electron transport and reactive oxygen species generation, GPD2 contributes to metabolic flexibility in nutrient stress and hypoxia-associated contexts. Dysregulated GPD2 function has been investigated in relation to metabolic disease phenotypes and altered bioenergetic states observed across cancer and endocrine-associated research models.
GPD2 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the GPD2 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within GPD2. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt GPD2 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of GPD2-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.